VOYAGER PHARMACEUTICAL REPORTS PROGRESS IN ENROLLMENT FOR ALZHEIMER'S STUDY

A A

Voyager Pharmaceutical has announced its progress in enrolling subjects into the ALADDIN studies, Phase III double-blind, placebo-controlled trials investigating the safety and efficacy of VP4896 in the treatment of mild-to-moderate Alzheimer's disease.

A total of 64 sites are now enrolling subjects for the study. Fifty-three of the sites are located in the U.S. and Canada, with the remaining 11 in Australia. During the first two-and-a-half months of recruitment, these sites have enrolled 57 subjects.